# Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

> **NCT01644643** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 345 (actual)

## Conditions studied

- Complicated Urinary Tract Infection
- Complicated Intra-abdominal Infection

## Interventions

- **DRUG:** Ceftazidime - Avibactam ( CAZ-AVI)
- **DRUG:** Best Available Therapy
- **DRUG:** Metronidazole

## Key facts

- **NCT ID:** NCT01644643
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2017-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01644643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01644643, "Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01644643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*